Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX04-O vs Ranibizumab in wAMD
NCT05003245Phase 3Completed
- Sponsor
- Henlius
- Start
- Nov 2021
- Primary completion
- May 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of HLX04-O in exudative macular degeneration, sponsored by Henlius. Started Nov 2021; status: completed.
02
Drugs
HLX04-O
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT05003245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003245.